Prosecution Insights
Prosecution Insights
10 pending office actions • 7 art units • 10 examiners • 0 of 10 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (10%) |
| §103 only | 1 (10%) |
| §112 only | 3 (30%) |
| Double-patenting + other | 2 (20%) |
| No statute on record | 3 (30%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SANG, HONG | 1 | 54.7% | +62.6% |
| NATARAJAN, MEERA | 1 | 62.3% | +17.6% |
| REDDIG, PETER J | 1 | 58.1% | +39.9% |
| CANELLA, KAREN A | 1 | 62.1% | +32.9% |
| SKELDING, ZACHARY S | 1 | 59.8% | +41.0% |
| YOUTCHOM PENDIE, EMMANUEL LED | 1 | 55.6% | +50.0% |
| MOSELEY II, NELSON B | 1 | 67.8% | +41.6% |
| MELCHIOR, JAMES RYLAND | 1 | 62.7% | +37.7% |
| FONTAINHAS, AURORA M | 1 | 38.0% | +49.1% |
| WEHBE, ANNE MARIE SABRINA | 1 | 57.4% | +42.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18178055 | PERSONALIZED IMMUNOTHERAPY AGAINST SEVERAL NEURONAL AND BRAIN TUMORS | FONTAINHAS, AURORA M | 153d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18178055 | PERSONALIZED IMMUNOTHERAPY AGAINST SEVERAL NEURONAL AND BRAIN TUMORS | FONTAINHAS, AURORA M | 153d overdue |
| 18297069 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | MELCHIOR, JAMES RYLAND | 60d overdue |
| 18315183 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | MOSELEY II, NELSON B | 27d |
| 18323577 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS | YOUTCHOM PENDIE, EMMANUEL LED | 34d |
| 18511308 | ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING PRAME | NATARAJAN, MEERA | 76d |
| 18533733 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST NON-SMALL CELL LUNG CANCER AND OTHER CANCERS | SANG, HONG | — |
| 18505361 | METHODS OF IDENTIFYING METASTATIC LESIONS IN A PATIENT AND TREATING THEREOF | REDDIG, PETER J | — |
| 18345700 | PEPTIDES, COMBINATION OF PEPTIDES, AND CELL BASED MEDICAMENTS FOR USE IN IMMUNOTHERAPY AGAINST URINARY BLADDER CANCER AND OTHER CANCERS | CANELLA, KAREN A | — |
| Art Unit | Apps |
|---|---|
| 1644 | 2 |
| 1643 | 1 |
| 1646 | 1 |
| 1647 | 1 |
| 1642 | 1 |
| 1675 | 1 |
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18533733 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST NON-SMALL CELL LUNG CANCER AND OTHER CANCERS | SANG, HONG | — | §102§103§112DP | Non-Final OA | — | Pending | Dec 08, 2023 |
| 18511308 | ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING PRAME | NATARAJAN, MEERA | 1643 | §112 | Non-Final OA | 76d | Pending | Nov 16, 2023 |
| 18505361 | METHODS OF IDENTIFYING METASTATIC LESIONS IN A PATIENT AND TREATING THEREOF | REDDIG, PETER J | 1646 | §103DP | Non-Final OA | — | Pending | Nov 09, 2023 |
| 18345700 | PEPTIDES, COMBINATION OF PEPTIDES, AND CELL BASED MEDICAMENTS FOR USE IN IMMUNOTHERAPY AGAINST URINARY BLADDER CANCER AND OTHER CANCERS | CANELLA, KAREN A | — | §112 | Non-Final OA | — | Pending | Jun 30, 2023 |
| 18343502 | TRANSFECTED T-CELLS AND T-CELL RECEPTORS FOR USE IN IMMUNOTHERAPY AGAINST CANCERS | SKELDING, ZACHARY S | 1644 | §112Other | Non-Final OA | — | Pending | Jun 28, 2023 |
| 18323577 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS | YOUTCHOM PENDIE, EMMANUEL LED | 1647 | Other | Non-Final OA | 34d | Pending | May 25, 2023 |
| 18315183 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | MOSELEY II, NELSON B | 1642 | Other | Non-Final OA | 27d | Pending | May 10, 2023 |
| 18297069 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | MELCHIOR, JAMES RYLAND | 1644 | §103Other | Non-Final OA | 60d overdue | Pending | Apr 07, 2023 |
| 18178055 | PERSONALIZED IMMUNOTHERAPY AGAINST SEVERAL NEURONAL AND BRAIN TUMORS | FONTAINHAS, AURORA M | 1675 | §101Other | Non-Final OA | 153d overdue | Pending | Mar 03, 2023 |
| 17553017 | T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME AGAINST PRAME POSITIVE CANCERS | WEHBE, ANNE MARIE SABRINA | 1634 | — | Non-Final OA | — | Pending | Dec 16, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial